Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis

Curr Opin Pharmacol. 2022 Dec;67:102292. doi: 10.1016/j.coph.2022.102292. Epub 2022 Oct 10.

Abstract

Psoriasis and psoriatic arthritis are chronic inflammatory diseases affecting the skin and joints, respectively. Psoriasis and psoriatic arthritis are associated with a high comorbidity burden as well as negative impact on quality of life. Impact on health-related quality of life is optimized when both skin and joint manifestations are effectively treated. The identification of key cytokines involved in disease pathogenesis has led to the development of several therapeutic options for psoriatic disease. When selecting a therapy, it is important to consider disease severity, psoriasis disease subtypes or domains of psoriatic arthritis, comorbidities, patient preference for treatment, among other factors. This review summarizes current biologic and small molecule treatment options as well as emerging therapies for moderate-to-severe adult plaque psoriasis and psoriatic arthritis.

Publication types

  • Review

MeSH terms

  • Adult
  • Arthritis, Psoriatic* / drug therapy
  • Arthritis, Psoriatic* / epidemiology
  • Biological Products* / therapeutic use
  • Comorbidity
  • Humans
  • Psoriasis* / drug therapy
  • Quality of Life

Substances

  • Biological Products